| |
Draft Agenda
(This document is not finalized.)
| |
| Monday, March 5, 2007 |
| 7:30 – 8:30 a.m. |
Registration |
| 8:30 – 9:00 a.m. |
Welcome, Introductions, and Meeting Overview
Nora D. Volkow, M.D.
Director
National Institute on Drug Abuse
Patricia A. Grady, Ph.D., R.N., F.A.A.N.
Director
National Institute of Nursing Research
Co-Chair
NIH Pain Consortium
Rebecca J. Patchin, M.D.
Secretary
Board of Trustees
American Medical Association
|
| 9:00 – 10:10 a.m. |
Panel I: Neurobiology of Opioids
Chair
Joseph Frascella, Ph.D.
National Institute on Drug Abuse
Opioid Receptors: The Basis of Pain Relief and Addiction
Mary Jeanne Kreek, M.D.
Rockefeller University
Opiate Analgesics: Pathways to Addiction
Christopher J. Evans, Ph.D.
University of California, Los Angeles
|
| 10:10 – 10:25 a.m. | Break |
| 10:25 – 11:20 a.m. | Panel I: Neurobiology of Opioids (Continued)
Pain and Addiction: Can We Actually See the Relationships?
Jon-Kar Zubieta, M.D., Ph.D.
University of Michigan
Discussant
Walter F. Stewart, Ph.D., M.P.H.
Geisinger Center for Health Research
|
| 11:20 a.m. – 12:30 p.m. |
Panel II: Epidemiology of Opioid Addiction and Pain
Chair
Wilson M. Compton, M.D., M.P.E.
National Institute on Drug Abuse
Opioid Addiction in the United States: From Opium to the Internet
David F. Musto, M.D., M.A.
Yale University
Epidemiology of Chronic Noncancer Pain and Opioid Treatment
Mark Sullivan, M.D.
University of Washington
|
| 12:30 – 1:30 p.m. |
Lunch (on your own) |
| 1:30 – 3:00 p.m. | Panel II: Epidemiology of Opioid Addiction and Pain (Continued)
History of Malignant Pain Treatment With Opioids
Kathleen M. Foley, M.D.
Memorial Sloan-Kettering Cancer Center
Epidemiology of Prescription Opioid Abuse in Young Women: Relationship to Pain
Carol J. Boyd, Ph.D., M.S.N., R.N.
University of Michigan
Discussant
David A. Fiellin, M.D.
Yale University
|
| 3:00 – 3:15 p.m. |
Break |
| 3:15 – 4:45 p.m. |
Panel III: Genetic Intersections of Pain and Addiction
Chair
David A. Thomas, Ph.D.
National Institute on Drug Abuse
Genetic Factors in the Transition From Acute Injury to Chronic Impairment
Ze’ev Seltzer, D.M.D.
University of Toronto
Genetic Vulnerability to Pain and Addiction
Kári Stefánsson, M.D., Dr.Med.
deCODE Genetics, Inc.
Discussant
Ming T. Tsuang, M.D., Ph.D., D.Sc.
University of California, San Diego
|
| 4:45 p.m. | Adjourn for the Day |
| Tuesday, March 6, 2007 |
| 8:30 – 8:45 a.m. |
Welcome Address
Elias A. Zerhouni, M.D.
Director
National Institutes of Health
|
| 8:45 – 10:15 a.m. |
Panel IV: Balancing Pain Relief and Risk for Addiction
Chair
Betty Tai, Ph.D.
National Institute on Drug Abuse
Aberrant Drug-Taking Behaviors During Pain Management—What Do We Know?
Steven D. Passik, Ph.D.
Memorial Sloan-Kettering Cancer Center
Safe and Effective Opioid Prescribing in the Internet Age
Nathaniel P. Katz, M.D., M.S.
Tufts University
Discussant
Norm Wetterau, M.D.
Tri-County Family Medicine
|
| 10:15 – 10:30 a.m. |
Break |
| 10:30 a.m. – 12:35 p.m. |
Panel V: Treatment Development: Hope on the Horizon
Chair
Linda L. Porter, Ph.D.
National Institute of Neurological Disorders and Stroke
New Opioid Formulations: Hope on the Horizon
Pamela P. Palmer, M.D., Ph.D.
University of California, San Francisco
Bivalent δ-µ Opioid Ligands: Potential for Pain Control Without Tolerance or Dependence
David J. Daniels, M.D., Ph.D.
University of Minnesota Medical School
Real-Time fMRI: A New Method for Controlling Targeted Brain Activation Through Training, With Application to Pain Control and Addiction
R. Christopher deCharms, Ph.D.
Omneuron, Inc.
Discussant
David Borsook, M.D. Ph.D.
Harvard University
|
| 12:35 – 1:05 p.m. |
Concluding Remarks
Introduction
Richard A. Denisco, M.D., M.P.H.
National Institute on Drug Abuse
Integrating Neuroscience and Clinical Practice To Better Address the Complex Needs of Pain Patients at Risk for Addiction
Howard L. Fields, M.D., Ph.D.
University of California, San Francisco
|
| 1:05 p.m. |
Adjournment |
|
|
